Horning J R, Zawada E T, Simmons J L, Williams L, McNulty R
University of South Dakota School of Medicine, Sioux Falls.
Chest. 1988 May;93(5):941-5. doi: 10.1378/chest.93.5.941.
We evaluated the safety and efficacy of transdermal clonidine (TC) in 23 patients with essential hypertension over a two-year period. Fourteen patients achieved control of blood pressure using TC alone. Six patients achieved control with a combination of TC and the diuretic chlorthalidone (CH). Three patients had control with CH alone or did not achieve control with either TC alone or TC plus CH and were dropped from the study. Of the 20 patients remaining in the study, six patients remained on TC or TC plus CH for the two-year study. Ten of the 20 patients quit the study because of skin reactions and four because of other side effects. No clinically significant changes were noted in serum or urinary laboratory parameters. Finally, TC was effective as long-term monotherapy for essential hypertension in only four of our patients. The major limitation is skin-related side effects.
我们在两年时间里评估了透皮可乐定(TC)对23例原发性高血压患者的安全性和疗效。14例患者仅使用TC就实现了血压控制。6例患者通过TC与利尿剂氢氯噻嗪(CH)联合使用实现了血压控制。3例患者单独使用CH实现了血压控制,或单独使用TC或TC加CH均未实现血压控制,因此退出了研究。在剩余的20例研究患者中,6例患者在为期两年的研究中继续使用TC或TC加CH。20例患者中有10例因皮肤反应退出研究,4例因其他副作用退出研究。血清或尿液实验室参数未发现临床上的显著变化。最后,在我们的患者中,只有4例患者使用TC作为原发性高血压的长期单一疗法有效。主要限制是与皮肤相关的副作用。